Gastric Cancer
Conditions
Interventions
Experimental group: intraperitoneal and intravenous Nab-Paclitaxel plus S-1
Sponsors
The Fourth Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Subjects aged over 18 years old; 2. Patients with locally advanced or metastatic / recurrent gastric adenocarcinoma confirmed by histology; 3. Patients with peritoneal metastasis complicated with malignant ascites who need to be diagnosed by peritoneal free cancer cell test or laparoscopy; 4. Patients whose solid tumor size can be measured according to the solid tumor response evaluation standard (recist1.1 standard); 5. ECOG = 1.5 * 10^9 / L, platelet >= 100 * 10^9 / L, hemoglobin >= 90 g / L; 7. Liver and kidney function: serum creatinine <= 1.5 times of upper limit of normal value; AST and alt <= 2.5 times of upper limit of normal value; total bilirubin <= 1.5 times of upper limit of normal value; 8. Patients have good compliance with the planned treatment, can understand the research process of this study and sign written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who received targeted drug therapy or immunotherapy within three months before enrollment; 2. Patients who received palliative chemotherapy within one month before enrollment; 3. Patients with uncontrolled hypertension, congestive heart failure or myocardial infarction within six months; 4. Patients with any other malignant tumor (except ovarian cancer and colon cancer) in the past 5 years; 5. Patients with untreated central nervous system diseases or symptomatic central nervous system metastases; 6. Pregnant or lactating women of childbearing age who refuse to take appropriate contraceptive measures during this trial; 7. Patients who need immunosuppressive therapy after organ transplantation; 8. Patients with uncontrolled severe infection or other serious accompanying diseases; 9. The investigator judged the patients who were not suitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective remission rate of ascites;Objective remission rate of tumour;Safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate of ascites;Disease control rate of tumour;Overall survival;Progression free survival; | — |
Countries
China
Contacts
Public ContactYin Fei
The Fourth Hospital of Hebei Medical University
Outcome results
None listed